REG - RTW Biotech Opp. - Transaction in Own Shares

RTW Biotech OpportunitiesAnnouncement

16/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240416:nRSP6853Ka&default-theme=true

RNS Number : 6853K  RTW Biotech Opportunities Ltd  16 April 2024

LEI: 549300Q7EXQQH6KF7Z84

16 April 2024

RTW Biotech Opportunities Ltd
(the "Company")

Transaction in Own Shares

The Company announces that on 15 April 2024 it bought back 200,000 of its own
shares, to be held as treasury shares, at an average price $1.31 per share.

Further details are set out below:

Number of shares held as treasury shares following this purchase: 8,803,791

Total shares in issue excluding treasury shares following this purchase:
385,486,512**

The Company has bought back these shares under the authority granted by
shareholders at its Annual General Meeting in June 2023, which permits the
Company to repurchase a maximum of 14.99% of its ordinary shares. The actual
number of shares repurchased by the Company will depend on market conditions.
This authority lasts until the next shareholder authority granted (expected to
be at the Annual General Meeting in 2024), or until expressly revoked by
shareholders.

The above figure of 385,486,512 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the Company under
the FCA's Disclosure and Transparency Rules.

No maximum consideration payable has been determined by the Company, but the
Company is unable to pay a price for any shares pursuant to the buyback which
would equate to a premium to the net asset value. It is the Company's current
intention to hold any shares bought back in treasury.

The Company has instructed Numis Securities Limited as its broker in respect
of its buyback transactions. This arrangement is in accordance with the UKLA
Listing Rules and the Company's general authority to repurchase shares.

**As per the "Completion of Acquisition" announcement published on 13 February
2024, the denominator used for the NAV per share calculation will exclude the
48,322,863 New RTW Bio Shares issued to RTW Biotech Opportunities Operating
Ltd in respect of its shareholding in Arix held by the Company.

For Further Information:

 

 RTW Investments, LP                           +44 (0)20 7959 6361
 Woody Stileman, Managing Director

 Krisha McCune, Director, Investor Relations

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund
focused on identifying transformative assets with high growth potential across
the biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSUVSVRSWUSAAR